VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
NCT02371447
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
39
Enrollment
OTHER
Sponsor class
Conditions
Bladder Cancer
Interventions
DRUG:
VPM1002BC
Sponsor
Swiss Cancer Institute